Comparative Pharmacology
Head-to-head clinical analysis: ELOXATIN versus EPIOXA HD EPIOXA KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELOXATIN versus EPIOXA HD EPIOXA KIT.
ELOXATIN vs EPIOXA HD/EPIOXA KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxaliplatin undergoes non-enzymatic biotransformation to form platinum-DNA adducts, leading to inhibition of DNA replication and transcription, and ultimately cell death. It is a third-generation platinum-based alkylating agent.
Oxaliplatin undergoes nonenzymatic biotransformation to active platinum derivatives that form inter- and intrastrand crosslinks in DNA, inhibiting DNA replication and transcription.
85 mg/m2 IV over 2 hours on day 1, repeated every 2 weeks (adjuvant); 85 mg/m2 IV over 2 hours on day 1, repeated every 2 weeks or 130 mg/m2 IV over 2 hours on day 1, repeated every 3 weeks (advanced disease).
EPIOXA HD: 100 mg/m² IV over 2 hours every 2 weeks. EPIOXA KIT: 100 mg/m² IV over 2 hours every 2 weeks.
None Documented
None Documented
Terminal half-life of ultrafilterable platinum: ~10-27 hours (mean ~14 hours); total platinum: ~40-50 hours. Clinical context: prolonged exposure due to tissue binding.
Terminal elimination half-life is approximately 0.7-1.1 hours (42-66 minutes) in patients with normal renal function; prolonged in renal impairment, necessitating dose adjustment.
Renal: ~54% of platinum excreted in urine within 48 hours; fecal: small amount (<2%); biliary excretion is minimal.
Primarily renal excretion; 70-80% of the dose is eliminated unchanged in urine within 48 hours; biliary/fecal excretion accounts for less than 10%.
Category C
Category C
Platinum-Based Antineoplastic
Platinum-Based Antineoplastic